Table 2.
All | GRT | GRT + rPRT | |
---|---|---|---|
Total tests - n | 1158 | 937 | 221 |
Male - % | 69.4 | 68.8 | 72.0 |
Age - median [IQR] | 41 [36-47] | 41 [36-47] | 40 [36-47] |
Caucasian - % | 79.5 | 79.9 | 77.8 |
HIV transmission group - % | |||
Homosexual | 39.5 | 40.7 | 34.4 |
Heterosexual | 38.0 | 37.3 | 41.2 |
IDU | 18.7 | 18.6 | 19.5 |
Other | 3.8 | 3.5 | 5.0 |
Current IDU or in drug maintenance program - % | 12.0 | 11.9 | 12.7 |
Baseline HIV-1 RNA (copies/mL)†- % | |||
Log RNA - Median [IQR] | 4.2 [3.2-4.9] | 4.2 [3.2-4.9] | 4.2 [3.3-4.9] |
= 50 | 2.6 | 3.0 | 0.9 |
51 - 500 | 10.6 | 10.6 | 10.7 |
501 - 1000 | 5.0 | 5.0 | 5.1 |
>1000 | 81.8 | 81.4 | 83.3 |
Baseline CD4 cell count (109)† - % | |||
Median [IQR] | 261 [168-387] | 260 [166-387] | 266 [180-390] |
<200 | 33.1 | 33.4 | 32.1 |
200 - 349 | 36.5 | 36.8 | 34.9 |
350 - 499 | 17.9 | 17.4 | 20.1 |
= 500 | 12.6 | 12.5 | 12.9 |
Hepatitis C¶ - % | 3.2 | 3.8 | 0.5 |
AIDS - % | 29.2 | 29.4 | 28.5 |
Number of previous ART regimens | |||
Median [IQR] | 2 [0-6] | 2 [0-6] | 2 [0-5] |
Treatment status at time of RT - % | |||
Naïve | 30.2 | 29.5 | 33.5 |
Off treatment | 14.3 | 15.5 | 9.1 |
Current | 55.5 | 55.1 | 57.5 |
ART after RT - % | |||
NNRTI | 26.3 | 24.8 | 32.6 |
PI non-boosted | 5.9 | 5.9 | 5.9 |
PI boosted | 58.8 | 60.7 | 50.7 |
Triple Nucleoside/Other | 9.1 | 8.6 | 10.9 |
Maximum missed doses of ART# -% | |||
0 | 49.9 | 51.2 | 45.9 |
1 | 15.1 | 13.5 | 20.2 |
2 | 12.9 | 13.5 | 11.0 |
>2 | 22.2 | 21.9 | 22.9 |
Missed 2 consecutive doses of ART# - % | 19.2 | 19.1 | 19.4 |
SHCS centre at time of RT - % | |||
Basel | 12.2 | 3.0 | 51.1 |
Bern | 14.8 | 10.8 | 31.7 |
Geneva | 19.3 | 23.8 | 0 |
Lausanne | 10.0 | 12.4 | 0 |
Lugano | 3.1 | 3.4 | 1.8 |
St. Gallen | 4.2 | 2.2 | 12.2 |
Zurich | 36.5 | 44.4 | 3.2 |
¶ Active/chronic hepatitis C
† Baseline is the time of RT. Labs closest to before or after the RT.
# In the year prior to RT.
RT = resistance test, GRT = genotypic RT, rPRT = replicative phenotypic RT, ART = antiretroviral therapy, IQR = interquartile range, IDU = intravenous drug use,